Enantioselective metabolism of primaquine by human CYP2D6

BACKGROUND: Primaquine, currently the only approved drug for the treatment and radical cure of Plasmodium vivax malaria, is still used as a racemic mixture. Clinical use of primaquine has been limited due to haemolytic toxicity in individuals with genetic deficiency in glucose-6-phosphate dehydrogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Fasinu, Pius S, Tekwani, Babu L, Nanayakkara, NP Dhammika, Avula, Bharathi, Herath, HMT Bandara, Wang, Yan-Hong, Adelli, Vijender R, Elsohly, Mahmoud A, Khan, Shabana I, Khan, Ikhlas A, Pybus, Brandon S, Marcsisin, Sean R, Reichard, Gregory A, McChesney, James D, Walker, Larry A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301821/
https://www.ncbi.nlm.nih.gov/pubmed/25518709
http://dx.doi.org/10.1186/1475-2875-13-507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301821/
https://www.ncbi.nlm.nih.gov/pubmed/25518709
http://dx.doi.org/10.1186/1475-2875-13-507

Ejemplares similares